Your browser is no longer supported. Please, upgrade your browser.
NVS Novartis AG daily Stock Chart
Novartis AG
Index- P/E25.81 EPS (ttm)2.88 Insider Own- Shs Outstand2.68B Perf Week-4.67%
Market Cap199.26B Forward P/E13.82 EPS next Y5.38 Insider Trans- Shs Float2.58B Perf Month-12.58%
Income7.02B PEG3.64 EPS next Q1.13 Inst Own9.90% Short Float0.21% Perf Quarter-17.31%
Sales50.36B P/S3.96 EPS this Y16.20% Inst Trans0.35% Short Ratio2.52 Perf Half Y-27.36%
Book/sh31.90 P/B2.33 EPS next Y11.81% ROA13.80% Target Price97.75 Perf Year-21.84%
Cash/sh2.21 P/C33.60 EPS next 5Y7.10% ROE24.10% 52W Range74.50 - 106.84 Perf YTD-13.61%
Dividend2.76 P/FCF68.01 EPS past 5Y3.20% ROI10.50% 52W High-30.43% Beta0.62
Dividend %3.71% Quick Ratio0.60 Sales past 5Y3.50% Gross Margin66.00% 52W Low-0.23% ATR1.78
Employees120000 Current Ratio0.90 Sales Q/Q-6.10% Oper. Margin19.20% RSI (14)31.47 Volatility1.42% 1.81%
OptionableYes Debt/Eq0.30 EPS Q/Q-40.80% Profit Margin36.20% Rel Volume1.08 Prev Close75.06
ShortableYes LT Debt/Eq0.17 EarningsJan 27 BMO Payout35.20% Avg Volume2.11M Price74.33
Recom1.80 SMA20-7.01% SMA50-10.85% SMA200-21.37% Volume2,290,679 Change-0.97%
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-23-08Upgrade Credit Suisse Underperform → Neutral
Aug-06-08Downgrade JP Morgan Overweight → Neutral
Jun-12-08Downgrade HSBC Securities Neutral → Underweight $52 → $49
Jun-04-08Upgrade Cowen & Co Neutral → Outperform
May-09-08Upgrade Bernstein Mkt Perform → Outperform
Apr-08-08Downgrade Bear Stearns Outperform → Peer Perform
Feb-29-08Initiated Cowen & Co Neutral
Feb-29-08Downgrade HSBC Securities Neutral → Underweight
Sep-06-07Initiated UBS Buy
Jul-18-07Downgrade Credit Suisse Neutral → Underperform
Jun-01-07Reiterated Prudential Overweight $64 → $62
Feb-07-16 04:01PM  3 Potential Blockbusters Moving the Needle for Big Pharma in 2016 at Motley Fool
07:20AM  Biogen Inc. Takes Aim at Johnson & Johnson at Motley Fool
Feb-06-16 08:40AM  Why Ophthotech Corporation Shares Tumbled 31% in January at Motley Fool
Feb-04-16 04:44PM  After The Martin Shkreli Circus, How Can We Fix Drug Pricing? at Forbes
02:20PM  ImmunoGen, Inc.'s Earnings Play the Amortization Blues at Motley Fool
12:55PM  [$$] Activist investors: hard drugs at Financial Times
09:40AM  Glaxo Tops Q4 Earnings, Revenues Rise Y/Y, 2016 View Intact
09:07AM  Novartis AG Earnings Analysis: 2015 By the Numbers
08:00AM  Drug Manufacturers - Major Equities Technical Updates -- TherapeuticsMD, Sanofi, Shire, and Novartis Accesswire
07:01AM  3 Value Stocks Near 52-Week Lows Worth Buying at Motley Fool
06:46AM  Morgan Freeman Visits DC On Cancer Prevention Day To Bring Good News: 70% Of Cancers Are Preventable at Forbes
Feb-03-16 12:42PM  [$$] GlaxoSmithKline: Playing the Waiting Game at The Wall Street Journal
11:32AM  Eli Lilly and Co.s 4Q15 Earnings: An Overview
10:34AM  [$$] Investors' Fears Eased as Glaxo Posts Solid Results at The Wall Street Journal
09:46AM  [$$] GlaxoSmithKline rules out break up as new drugs boost sales at Financial Times
09:33AM  GSK refuses to be bounced into early consumer unit spin-off
Feb-02-16 10:41PM  Drugs giant GSK says annual net profits triple AFP
Feb-01-16 04:48PM  Sun hopes cut-price generic Gleevec will win third of U.S. market
04:30PM  Can GlaxoSmithKline (GSK) Q4 Earnings Surprise Estimates?
04:07PM  Novartiss 2015 Revenues Rise 5% at Constant Currencies
04:07PM  Novartis Reports Operational Growth in 4Q15
09:30AM  New Strong Sell Stocks for February 1st
07:05AM  Elanco Contributed ~15% of Total Revenues for Eli Lilly
12:04AM  What Does Novartis Expect from Pharmaceuticals?
Jan-31-16 02:54AM  Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US at noodls
02:54AM  Novartis Pharmaceuticals collaborates with Qualcomm in digital innovation with the Breezhaler(TM) inhaler device to treat COPD at noodls
02:54AM  Novartis delivered strong sales growth and core margin expansion (cc) in 2015; announces plans to accelerate growth at Alcon, streamline Group operations at noodls
02:54AM  Novartis continues to grow immuno-oncology pipeline through collaboration and licensing agreement with Surface Oncology at noodls
Jan-30-16 01:04PM  NOVARTIS AG Financials
Jan-29-16 03:49PM  AstraZenecas 4Q15 Revenue Estimates: Expect a Fall!
03:13PM  What do Analysts Expect from Sanofis 4Q15 Earnings?
02:02PM  The 3 Most Important Numbers When GlaxoSmithKline Reports Its Fourth-Quarter Results at Motley Fool
Jan-28-16 05:37PM  Heres the Company Thats the Closest to Developing a Zika Vaccine at Fortune
04:20PM  Radius (RDUS) Collaborates With Novartis Targeting Cancer
02:33PM  Why Incyte's Shares Crashed 12% Today at Motley Fool
10:25AM  Novartis (NVS) Lags Q4 Earnings & Revenues, Alcon Down
08:07AM  Eylea Could Help Regeneron Focus on the Eye Therapy Segment
08:05AM  Is Another Big Transformation on the Way for GlaxoSmithKline? at Motley Fool
12:44AM  [$$] Business Watch at The Wall Street Journal
Jan-27-16 05:05PM  Radius Health Announces Clinical Collaboration With a Leading Pharmaceutical Company to Evaluate RAD1901 Combination Regimens in Advanced Breast Cancer at noodls -5.38%
04:30PM  Radius Health Announces Clinical Collaboration With a Leading Pharmaceutical Company to Evaluate RAD1901 Combination Regimens in Advanced Breast Cancer GlobeNewswire
04:07PM  Analysts Estimate Eli Lillys EPS at $0.78 in 4Q15
02:38PM  [$$] Novartis Profit Dives 57% at The Wall Street Journal
01:29PM  Novartis and the 'T' Word at Bloomberg
11:48AM  US insurers dragging feet on covering new drugs, Novartis says Reuters
09:55AM  Apple worries; Boeing loses altitude; Biogen blasts off
09:00AM  [$$] Novartis revamps Alcon eyecare division at Financial Times
08:53AM  Novartis hires Hospira's $90 mln man to save Alcon Reuters
07:54AM  Novartis profits plunge
07:40AM  Wall St. awaits Fed; Apple iPhone sales slow; Trump's Twitter vs. TV
07:40AM  [$$] Novartis: Out of Sync and Out of Sorts at The Wall Street Journal
06:12AM  European Stocks Fall Amid Disappointing Earnings at TheStreet
04:15AM  European shares pushed down as weak earnings weigh on markets
04:14AM  Novartis (NVS) Posts Lower-Than-Expected Earnings in Q4
03:21AM  European shares lose ground as Novartis and BASF fall
02:14AM  Novartis to overhaul Alcon but no 'quick fix': CEO at CNBC
01:08AM  Novartis Quarterly Profit Misses Estimates Amid Alcon Woes at Bloomberg
Jan-26-16 11:15AM  Juno, Kite Valuations at Risk From Simpler T-Cell Cancer Therapy at TheStreet
08:07AM  Big Pharma's bet on Big Data creates opportunities and risks Reuters
07:20AM  GSKs 4Q15 Earnings: What to Expect from the Vaccines Business
Jan-25-16 04:16PM  Analyzing the T. Rowe Price European Stock Funds 2015 Holdings
03:30PM  Novartis (NVS) to Report Q4 Earnings: Will It Disappoint?
09:51AM  Regeneron: Sell on Patent Fears, Chardan Says at
Jan-22-16 01:20PM  Eli Lillys 4Q15 Revenue Estimates: Expect Growth!
12:12AM  Novartis Stock: A Dividend Analysis (NVS) at Investopedia
Jan-21-16 08:32AM  How Novartis Probably Has a Cure for What Ails You at Investopedia
Jan-20-16 09:28PM  Drug industry to fight superbugs together with governments
11:06AM  AbbVie Expects Imbruvica Revenues to Reach $5 Billion in 2020
Jan-19-16 12:30PM  As the World Economic Forum Starts in Davos, Watch These 3 Swiss Stocks
10:07AM  How Will Sandoz Perform in Novartiss 4Q15 Earnings?
09:15AM  The Eurozone Economy in 2016 and Beyond: World Bank Projections
Jan-18-16 03:25PM  Novartis Gets FDA Nod for Label Expansion of Cosentyx
07:18AM  Novartiss 4Q15 Revenue Estimates: Expect a Fall!
07:18AM  Novartis Will Report Its 4Q15 Earnings on January 27
Jan-15-16 05:30PM  Juno Buyout Puts Single-Cell Sequencing In Spotlight at Investor's Business Daily
01:30PM  A Close Look at Teva Pharmaceuticals Specialty Business
Jan-14-16 06:50PM  [$$] Oversold Novartis: Juicy Yield, $9 Billion Pipeline at
10:10AM  5 Reasons Why GlaxoSmithKline Shareholders Should Be Excited About the Future at Motley Fool
Jan-13-16 04:45PM  Roche's NDA for Lymphocytic Leukemia Drug Accepted by FDA
01:07PM  Healthcare Stocks: Are These 2016's Best? at Investopedia
10:45AM  GlaxoSmithKlines 4Q15 Revenues Expected to Rise
Jan-12-16 05:10PM  OHSU spinoff raises $11M to tackle rare brain disease at
04:27PM  Pfizer, Allergan CEOs: Tie-up aims for growth, not cost cuts
04:01PM  Coherus Biosciences and Baxalta Take Aim at Amgen and Pfizer at Motley Fool
07:30AM  Group B Strep Vaccine For Pregnant Women Found Safe, Effective In Phase 2 Trial at Forbes
Jan-11-16 03:55PM  No quick fix seen for Novartis's troubled Alcon unit
01:36PM  Berkshire Hathaway, Wells Fargo, China Mobile, Novartis, Bank of America Reach 52-Week Lows
01:15PM  Novartis signs $170M immuno-oncology pact with Surface Reuters
11:02AM  Geron Corporation Exploded 49% Higher in 2015 -- Here's Why at Motley Fool
07:30AM  Group B Strep Vaccine For Pregnant Women Found Safe, Effective In Phase 2 Trial at Forbes
Jan-10-16 10:20AM  Why Opthotech Corporation Shares Skyrocketed by 75% in 2015 at Motley Fool
Jan-08-16 01:27PM  Cancer Deaths Are Plummeting to Lowest in Decades at Fortune
11:25AM  Cambridge biotech to test non-addictive ADHD drug in 145 patients at
08:06AM  Mercks 4Q15 Earnings: Expected Growth Contributors
Jan-07-16 04:03PM  [$$] West Sussex announces plans for science hub at Financial Times
02:51PM  GenVec returns to hearing loss research with new Novartis deal at
12:31PM  Analysts Expect Merck & Co.s Revenue to Fall in 4Q15
09:15AM  3 European Companies That Offer Big Dividends at TheStreet
Jan-06-16 09:03AM  Will 2016 Be Regeneron Pharmaceuticals Inc.'s Best Year Yet? at Motley Fool
Jan-05-16 09:15AM  4 Stocks to Help You Sleep Easy as Market Falls at 24/7 Wall St.
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Pharmaceuticals, Alcon, and Sandoz. The Pharmaceuticals segment offers patented prescription medicines for oncology, neuroscience, retina, immunology and dermatology, respiratory, cardio-metabolic, established medicines, and cell and gene therapies. The Alcon segment provides eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye, and over-the-counter medicines for the eye; and contact lenses and lens care products. The Sandoz segment offers generic prescription medicines that include active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The company has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and with Caribou Biosciences for the development of drug discovery tools. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.